$PFE issued a disappointing update concerning its Phase 3 early breast cancer Palbociclib Collaborative Adjuvant Study trial results. The Austrian Breast and Colorectal Cancer study group and the Alliance Foundation Trials, LLC, reported that following an analysis, #MarketUpdate https://t.co/XPci0GKAot